The global tyrosine kinase JAK inhibitors market is expected to grow at a CAGR of around 8.5% during the forecast period, from 2021 to 2030. The growth of this market is mainly driven by the increasing prevalence of autoimmune disorders and cancer, which are major indications for JAK inhibitors.
The global tyrosine kinase JAK inhibitors market is segmented on the basis of type, application and region. On the basis of type, it is classified into tofacitinib, ruxolitinib and baricitinib. On the basis of application, it is classified into rheumatoid arthritis (RA), polycythemia vera (PCV) and myelofibrosis (MF). On the basis of region, it has been segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa regions.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease is driving the growth of the market for Tyrosine Kinase JAK Inhibitors.
- The increasing number of patients with cancer and other life-threatening diseases is also driving the growth of this market.
- Increasing research and development activities in this field are also contributing to the growth of this market.
- Increasing awareness about these drugs among physicians will drive their adoption in clinical practice.
Industry Growth Insights published a new data on “Tyrosine Kinase JAK Inhibitors Market”. The research report is titled “Tyrosine Kinase JAK Inhibitors Market research by Types (Tofacitinib, Ruxolitinib, Baricitinib), By Applications (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), Others), By Players/Companies Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, Astellas Pharma, Celgene, CTI BioPharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tyrosine Kinase JAK Inhibitors Market Research Report
By Type
Tofacitinib, Ruxolitinib, Baricitinib
By Application
Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), Others
By Companies
Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, Astellas Pharma, Celgene, CTI BioPharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Tyrosine Kinase JAK Inhibitors Market Report Segments:
The global Tyrosine Kinase JAK Inhibitors market is segmented on the basis of:
Types
Tofacitinib, Ruxolitinib, Baricitinib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Incyte
- Novartis
- Eli Lilly
- Gilead
- Sanofi
- Galapagos
- AbbVie
- Vertex
- Teva
- Astellas Pharma
- Celgene
- CTI BioPharma
Highlights of The Tyrosine Kinase JAK Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tofacitinib
- Ruxolitinib
- Baricitinib
- By Application:
- Rheumatoid Arthritis (RA)
- Polycythemia Vera (PCV)
- Myelofibrosis (MF)
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tyrosine Kinase JAK Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tyrosine kinase inhibitors (TKIs) are a type of medication that block the activity of tyrosine kinases. Tyrosine kinases are enzymes that play a role in the cell's signaling pathway. TKIs can help to prevent or treat diseases such as cancer, Crohn's disease, and psoriasis.
Some of the major companies in the tyrosine kinase jak inhibitors market are Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, Astellas Pharma, Celgene, CTI BioPharma.
The tyrosine kinase jak inhibitors market is expected to grow at a compound annual growth rate of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tyrosine Kinase JAK Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tyrosine Kinase JAK Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tyrosine Kinase JAK Inhibitors Market - Supply Chain
4.5. Global Tyrosine Kinase JAK Inhibitors Market Forecast
4.5.1. Tyrosine Kinase JAK Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tyrosine Kinase JAK Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tyrosine Kinase JAK Inhibitors Market Absolute $ Opportunity
5. Global Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
5.3.1. Tofacitinib
5.3.2. Ruxolitinib
5.3.3. Baricitinib
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
6.3.1. Rheumatoid Arthritis (RA)
6.3.2. Polycythemia Vera (PCV)
6.3.3. Myelofibrosis (MF)
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tyrosine Kinase JAK Inhibitors Demand Share Forecast, 2019-2026
9. North America Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
9.4.1. Rheumatoid Arthritis (RA)
9.4.2. Polycythemia Vera (PCV)
9.4.3. Myelofibrosis (MF)
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
9.7.1. Tofacitinib
9.7.2. Ruxolitinib
9.7.3. Baricitinib
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tyrosine Kinase JAK Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
10.4.1. Rheumatoid Arthritis (RA)
10.4.2. Polycythemia Vera (PCV)
10.4.3. Myelofibrosis (MF)
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
10.7.1. Tofacitinib
10.7.2. Ruxolitinib
10.7.3. Baricitinib
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tyrosine Kinase JAK Inhibitors Demand Share Forecast, 2019-2026
11. Europe Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
11.4.1. Rheumatoid Arthritis (RA)
11.4.2. Polycythemia Vera (PCV)
11.4.3. Myelofibrosis (MF)
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
1.7.1. Tofacitinib
11.7.2. Ruxolitinib
11.7.3. Baricitinib
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tyrosine Kinase JAK Inhibitors Demand Share, 2019-2026
12. Asia Pacific Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
12.4.1. Rheumatoid Arthritis (RA)
12.4.2. Polycythemia Vera (PCV)
12.4.3. Myelofibrosis (MF)
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
12.7.1. Tofacitinib
12.7.2. Ruxolitinib
12.7.3. Baricitinib
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tyrosine Kinase JAK Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Application
13.4.1. Rheumatoid Arthritis (RA)
13.4.2. Polycythemia Vera (PCV)
13.4.3. Myelofibrosis (MF)
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Size and Volume Forecast by Type
13.7.1. Tofacitinib
13.7.2. Ruxolitinib
13.7.3. Baricitinib
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tyrosine Kinase JAK Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tyrosine Kinase JAK Inhibitors Market: Market Share Analysis
14.2. Tyrosine Kinase JAK Inhibitors Distributors and Customers
14.3. Tyrosine Kinase JAK Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Incyte
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Gilead
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Galapagos
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AbbVie
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Vertex
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Teva
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Astellas Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Celgene
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. CTI BioPharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
